Skip to main content

Advertisement

Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

Fig. 2

Types of a preindex and b postindex cytoreductive medications by PV risk category. a Data were assessed during the preindex period (January 1 to December 31, 2012). Busulfan was reported by 0.3 and 0.6% of high-risk and low-risk patients, respectively, who received preindex cytoreductive therapy. b Data were assessed during the postindex period (January 1, 2013, to December 31, 2014). PV polycythemia vera

Back to article page